Patents Assigned to Mochida Pharmaceutical Co., Ltd.
  • SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID
    Publication number: 20140057981
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD
    Inventors: Hirosato FUJII, Motoo YAMAGATA
  • CYCLIC AMIDE DERIVATIVE
    Publication number: 20140057871
    Abstract: [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like. [Means of solving the problem] A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; h is 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J1a is —CR11a—, N; J2 is —CR12aR12b—, —CR12c—; T is —CH2—, O, —S(O)i— (i is an integer of 0 to 2) or —NR7—; X is O, S, or —NR7—; ring A?? is a benzene ring, a pyridine ring; ring B? is a benzene ring, a pyridine ring, a pyrimidine ring; and R1 to R14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    Type: Application
    Filed: April 11, 2012
    Publication date: February 27, 2014
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Munetaka Ohkouchi, Muneyoshi Makabe
  • ANTI-CD14 ANTIBODY FUSION PROTEIN
    Publication number: 20140050727
    Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
    Type: Application
    Filed: August 21, 2013
    Publication date: February 20, 2014
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shoji FURUSAKO, Kazuyuki NAKAYAMA, Yoshitaka HOSAKA, Tetsushi KAWAHARA, Masaki NAKAMURA, Takashi TAKEUCHI
  • 3-hydroxyisothiazole 1-oxide derivatives
    Patent number: 8629102
    Abstract: [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 14, 2014
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Munetaka Ohkouchi
  • Self-emulsifying composition of OMEGA3 fatty acid
    Patent number: 8618168
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: December 31, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hirosato Fujii, Motoo Yamagata
  • ?3 fatty acid compound preparation
    Patent number: 8609138
    Abstract: Provided is a compound preparation including at least one selected from the group consisting of ?3 polyunsaturated fatty acids and pharmaceutically acceptable salts and esters thereof and at least one selected from the group consisting of statin compounds and pharmaceutically acceptable salts thereof. The compound preparation is in a form of a soft capsule having a capsule coating with a pH of 7.0 to 9.5. The compound preparation suppresses the decomposition of the statin compounds and/or the modification/insolubilization of the capsule coating. A medical use for the compound preparation, a method of manufacturing the compound preparation and a method of using the compound preparation are also provided.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: December 17, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hirosato Fujii, Hiromitsu Ito, Motoo Yamagata
  • AGENT FOR INHIBITING ELEVATION IN BLOOD GLUCOSE LEVEL
    Publication number: 20130303614
    Abstract: The present invention relates to a suppressor for increase in postprandial blood glucose level, which contains an ester of EPA or DHA as an active ingredient and is characterized by being administered between meals. The present invention provides a suppressor for increase in blood glucose level which is highly safe and has desired properties including storage stability, particularly a means for preventing postprandial hyperglycemia.
    Type: Application
    Filed: November 8, 2011
    Publication date: November 14, 2013
    Applicants: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hideo Kanehiro, Mariko Imai
  • METHOD FOR PREDICTION OF PROGNOSIS OF SEPSIS
    Publication number: 20130288276
    Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.
    Type: Application
    Filed: January 10, 2012
    Publication date: October 31, 2013
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., Mitsubishi Chemical Medience Corporation
    Inventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo
  • METHOD FOR SELECTING PATIENT TO BE GIVEN DRUG FOR TREATING SEPTICEMIA
    Publication number: 20130280252
    Abstract: The present invention is a method for selecting a patient to be given a drug for treating septicemia the mode of action of which is to interrupt toll-like receptor 4-derived intracellular signaling. The provided method comprises a step for measuring sCD14-ST in a blood sample from a subject, a step for comparing the measured value with a cut-off value, and a step for selecting a patient as the patient to be given the drug for the treatment of septicemia when the measured value of the sample of that patient is positive in comparison to the cut-off value. The present invention makes it possible to provide a drug to be given to a specific patient to treat septicemia, the mode of action of which is to interrupt toll-like receptor 4-derived intracellular signaling, and to appropriately select the patient to be given the drug and the administration timing or dose.
    Type: Application
    Filed: January 5, 2012
    Publication date: October 24, 2013
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mariko Imai, Kamon Shirakawa
  • 3-hydroxyisothiazole 1-oxide derivatives
    Patent number: 8557766
    Abstract: [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: October 15, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Munetaka Ohkouchi
  • Polynucleotide encoding anti-CD14 antibody fusion protein
    Patent number: 8541565
    Abstract: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: September 24, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shoji Furusako, Kazuyuki Nakayama, Yoshitaka Hosaka, Tetsushi Kawahara, Masaki Nakamura, Takashi Takeuchi
  • Anti-platelet membrane glycoprotein VI monoclonal antibody
    Patent number: 8524870
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 3, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING-SOLUBLE GPVI
    Publication number: 20130217050
    Abstract: Provided are an agent for noninvasively and easily diagnosing Alzheimer's disease, a method for diagnosing Alzheimer's disease through the measurement, and a measurement kit therefor. The present invention relates to a reagent for measuring soluble GPVI (sGPVI) in a human body fluid; an agent for specifically diagnosing Alzheimer's disease, said agent comprising a reagent for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid; and a method for specifically diagnosing Alzheimer's disease, said method comprising a step for measuring the concentration of sGPVI in a collected human body fluid and a step for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid.
    Type: Application
    Filed: September 6, 2011
    Publication date: August 22, 2013
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Katsuki Naitoh, Yoshitaka Hosaka
  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
    Publication number: 20130217690
    Abstract: [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 22, 2013
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Mochida Pharmaceutical Co., Ltd.
  • NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
    Publication number: 20130210721
    Abstract: [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: MOCHIDA PHARMACEUTICAL CO., LTD.
  • CYCLIC AMIDE DERIVATIVE
    Publication number: 20130203739
    Abstract: [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR7—; J1 is —CR11aR11b— or —NR11c—; J2 is —CR12aR12b— or —NR12c—; and R1 to R12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    Type: Application
    Filed: October 11, 2011
    Publication date: August 8, 2013
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Munetaka Ohkouchi, Muneyoshi Makabe
  • COMPOSITION FOR TREATMENT OF CARTILAGE DISEASE
    Publication number: 20130189231
    Abstract: The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
    Type: Application
    Filed: January 9, 2013
    Publication date: July 25, 2013
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: MOCHIDA PHARMACEUTICAL CO. LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
  • 3-hydroxy-5-arylisothiazole derivative
    Patent number: 8476287
    Abstract: [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR7—; and R1 to R7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: July 2, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Akihiro Okano, Naoto Kosuga, Munetaka Ohkouchi, Daido Hotta, Muneyoshi Makabe
  • Preventive or therapeutic drug for Alzheimer-type dementia
    Patent number: 8461141
    Abstract: It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ?-3 polyunsaturated fatty acid and thyroid hormone are used in combination.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: June 11, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kiyoshi Hashizume
  • 3-hydroxy-5-arylisoxazole derivative
    Patent number: 8455500
    Abstract: [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: June 4, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Akihiro Okano, Munetaka Ohkouchi